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biomarker analyses were mainly performed during cycle 1 
and 2.
Results Total of six EGFR-mutant NSCLC patients 
including one EGFR-TKI naïve patient received patritumab 
Process 2 formulation combined with erlotinib. No dose-
limiting toxicities were observed. The most frequent AEs 
were gastrointestinal or skin toxicities, which were gener-
ally mild and manageable. One patient discontinued from 
study due to reversible grade 3 interstitial lung disease. 
The mean area under the curve (AUC) value was 2640 μg/
day/mL; the Cmax value was 434 μg/mL, respectively. The 
median progression-free survival (95% confidence interval) 
was 220.0 (100.0–363.0) days. HER3 ligand heregulin was 
detected in serum from only a patient that maintained most 
durable stable disease.
Conclusions Patritumab Process 2 formulation in com-
bination with erlotinib was well tolerated compatible with 
favorable PK profile in Japanese patients with advanced 
NSCLC.
Keywords Patritumab · Anti-HER3 monoclonal 
antibody · Pharmacokinetics · Phase 1 study
Introduction
The human epidermal growth factor receptor-3 (HER3) 
is a member of the HER (EGFR/ErbB) receptor family 
consisting of four closely related type 1 transmembrane 
receptors (EGFR, HER2, HER3, and HER4). HER recep-
tors are part of a complex signaling network intertwined 
with the Ras/Raf/MAPK, PI3K/AKT, JAK/STAT, and 
PKC signaling pathways. HER3 is expressed in many 
normal tissues and in a variety of solid tumors, including 
non-small cell lung cancer (NSCLC) [1–4], and increased 
Abstract 
Background This phase 1 study evaluated the safety, tol-
erability, pharmacokinetics and efficacy of patritumab 
(U3-1287) Process 2, a new formulation of fully human 
anti-HER3 monoclonal antibody in combination with erlo-
tinib, an epidermal growth factor receptortyrosine kinase 
inhibitor (EGFR-TKI) in prior chemotherapy treated Japa-
nese patients with advanced non-small cell lung cancer 
(NSCLC).
Methods Patients received intravenous patritumab Pro-
cess 2 formulation at 9 mg/kg every 3 weeks after initiation 
of 18 mg/kg loading dose combined with continuous daily 
dose of erlotinib (150 mg QD) until any of the withdrawal 
criteria are met. Adverse events (AEs) were assessed using 
CTCAE v4.0 and tumor response was assessed using 
RECIST v1.1. Full pharmacokinetic sampling and serum 
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levels of HER3 have been associated with a negative clin-
ical prognosis, including survival in several tumor types 
[5–8]. HER3 is the only HER family member that lacks 
tyrosine kinase activity because of an amino acid sub-
stitution in the conserved kinase domain. Thus, interac-
tions of HER3 with binding partners are essential for its 
biological activity [9]. In particular, HER3 potently acti-
vates downstream phosphatidylinositol-3-kinase (PI3K) 
and AKT pathway signaling by directly binding to PI3K 
through six consensus phosphotyrosinesites [10]. Recent 
preclinical and clinical data also suggest that HER3 is 
involved in resistance to other HER receptor-targeted 
therapeutics [11–15]. Since HER3 has limited kinase 
activity, several newly developed monoclonal antibod-
ies (mAbs) are being explored to target HER3 for cancer 
therapy.
Patritumab (U3-1287) is a fully human monoclonal 
immunoglobulin G1 (IgG1) antibody directed against 
HER3, thereby inhibiting ligand binding [heregulin alpha 
(HRG-α) and heregulin beta (HRG-β)] and receptor acti-
vation and induces HER3 down-regulation. Functionally, 
patritumab inhibits tumor cell proliferation, survival, and 
anchorage-independent growth in vitro, and inhibits growth 
of HER3 expressing xenograft tumor models in  vivo 
[16–19]. In addition, the combined use of patritumab with 
erlotinib, an epidermal growth factor receptor-tyrosine 
kinase inhibitor (EGFR-TKI), led to increased inhibition of 
tumor proliferation, compared with patritumab alone [18].
In a first-in-human phase 1 study (ClinicalTrials.gov 
Identifier: NCT00730470), the safety and tolerability of 
patritumab were evaluated up to the dose of 20 mg/kg with-
out dose-limiting toxicities (DLTs) [20]. In another phase 
1 study (ClinicalTrials.jp Identifier: JapicCTI-101,262) 
in Japanese patients, patritumab was well tolerated up to 
18 mg/kg without DLTs and PK profile was similar to the 
US phase I study [21]. Regarding the combined approaches 
of former formulation of patritumab (patritumab Process 
1) with other molecular targeting agents, both erlotinib in 
patients with NSCLC and trastuzumab and paclitaxel in 
patients with HER2 overexpressing metastatic breast can-
cer were evaluated [22, 23]. The drug substance and prod-
uct for use in nonclinical studies, phase 1 clinical studies, 
and phase 2 clinical studies during early phases of develop-
ment of patritumab were manufactured using Manufactur-
ing Method Process 1. Subsequently, a new method, Pro-
cess 2 was developed to manufacture the drug substance 
and product for use in a global phase 3 study, with the aim 
of increasing the yield of the target protein and improving 
properties of the drug substance and/or product. Based on 
both safety profile and clinical activities of patritumab Pro-
cess 1 combined with EGFR-TKI, erlotinib in patients with 
advanced NSCLC, this study evaluated that the safety and 
pharmacokinetics of patritumab Process 2 in combination 
with erlotinib and potential biomarkers related to patritu-
mab were also evaluated.
Materials and methods
Patient eligibility
This study was conducted based on the Declaration of Hel-
sinki and the Guidelines for the Clinical Evaluation Meth-
ods of Anti-Cancer Drugs in Japan (Japanese Ministry of 
Health, Labour, and Welfare notification, November 1, 
2005). The study was approved by the institutional review 
board of study site.
The main eligibility criteria were as follows: a histologi-
cally or cytologically confirmed diagnosis of stage IIIB/IV 
NSCLC in a patient who had experienced disease progres-
sion while on the standard therapy or in a patient intoler-
ant of, or not eligible for the standard therapy (prior EGFR-
TKIs therapy allowed); a patient age ≥ 20 years; an Eastern 
Cooperative Oncology Group (ECOG) performance status 
of 0 or 1; a life expectancy of more than 3 months; and ade-
quate hematologic, hepatic, and renal functions. The exclu-
sion criteria included the administration of chemotherapy, 
radiotherapy, or biological therapy in the 4 weeks (2 weeks 
for palliative radiotherapy and kinase inhibitors) prior to 
enrollment; other active malignancies; history or presence 
of interstitial lung disease (ILD); history (within 6 months 
before enrollment) or presence of severe cardiovascular 
or cerebrovascular disease, pulmonary thrombosis, deep 
vein thrombosis, or other clinically severe pulmonary dis-
ease; any of the following complications, including clini-
cally severe infections requiring systemic administration 
of an antimicrobial agent, antiviral agent or other agents; 
presence of chronic diarrhea, inflammatory bowel disease 
or partial ileus; presence of peptic ulcer; fluid retention 
requiring treatment; corneal disease; uncontrolled diabetes 
mellitus; hypertension; psychiatric symptoms; appositive 
test for hepatitis B virus surface antigen, hepatitis C virus 
antibody or human immunodeficiency virus antibody; his-
tory of a bleeding diathesis; and history of serious hyper-
sensitivity to drugs containing polysorbate 20. All patients 
provided informed consent, and the study was conducted 
in accordance with the current Good Clinical Practice 
standards. This study was registered at ClinicalTrials.jp 
Identifier:JapicCTI-152,841.
Study design and evaluation
This study was an open-label, non-randomized, phase 1 
study of patritumab Process 2 formulation of fully human 
anti-HER3 monoclonal antibody in combination with erlo-
tinib in Japanese patients with advanced NSCLC that was 
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conducted at single site in Japan. The primary objective 
was to evaluate the safety and tolerability of patritumab 
Process 2 formulation combined with erlotinib in Japa-
nese patients with advanced NSCLC. Secondary objectives 
were to assess the PK profile, preliminary tumor response, 
to evaluate incidence of anti-patritumab antibody, and to 
explore patritumab-related biomarkers. Patritumab Process 
2 formulation was administered as a 60-min intravenous 
(i.v.) infusion at 18 mg/kg for the initial dose and at 9 mg/
kg for the second and subsequent doses every 3 weeks in 
combination with an oral daily dose of erlotinib 150  mg 
(150  mg QD). Patients received fixed dose of patritumab 
Process 2 formulation at 9 mg/kg every 3 weeks after ini-
tiation of 18 mg/kg loading dose combined with erlotinib 
at 150 mg QD in single dose cohort until any of the with-
drawal criteria are met. Withdrawal criteria are disease 
progression, unacceptable toxicity, ILD, dosing postponed/
discontinued for more than 3 weeks, subject’s request to 
withdraw from study treatment, and other instances in 
which the study cannot be continued in the judgment of the 
investigator. The initial 21 days after the first administra-
tion (cycle 1) were regarded as the DLT evaluation period, 
and six patients were enrolled at single dose cohort. In 
the DLT assessments, if none/one of the six patients had 
a DLT that dose was considered to be tolerable. Adverse 
events (AEs) were graded using the National Cancer Insti-
tute Common Terminology Criteria for AEs, version 4.0. 
A DLT was defined as any of the following events occur-
ring during cycle 1 (the initial 21 days) as related to either 
patritumab or erlotinib: (1) grade 3 or higher febrile neutro-
penia, or persistent (more than 7 days) grade 4 neutropenia; 
(2) grade 4 thrombocytopenia, or grade 3 thrombocytope-
nia requiring blood transfusion; (3) uncontrollable grade 3 
or higher fatigue, anorexia, nausea, vomiting, skin disorder 
(e.g., skin eruption, urticaria), and diarrhea despite maxi-
mal supportive therapy; (4) grade 3 or higher toxicity, with 
the exception of (1)–(3) as well as pyrexia without neutro-
penia, transient electrolyte abnormality, and transient lab-
oratory abnormality not requiring treatment and without 
clinical symptoms; and (5) toxicity requiring suspension 
of erlotinib therapy for more than 7 days during the DLT 
evaluation period. Tumor response was determined for all 
patients with measurable and/or non-measurable lesions 
according to Response Evaluation Criteria in Solid Tumors 
(RECIST version 1.1). Tumor measurements by CT or MRI 
were obtained at baseline, every 6 weeks thereafter and 
Cycle 1 Day 21.
Pharmacokinetics
Pharmacokinetics were evaluated in all patients received 
patritumab Process 2 formulation in combination with 
erlotinib. Blood samples were collected at pre-dose and 1 
(end of infusion), 4, 7, 24, and 72 h after the start of first 
dose infusion, on Days 8 and 15 of Cycle 1, and on Day 1 
of Cycles 2, 3, and 4. Serum concentrations of patritumab 
Process 2 formulation were determined by enzyme-linked 
immunosorbent assay (ELISA). Pharmacokinetic param-
eters after the first dose were calculated by non-compart-
mental analysis using WinNonlin (Ver.6.2 CERTARA 
G.K., Japan).
Pharmacokinetic statistical analyses were performed 
using SAS System Release 9.2 (SAS Institute Japan Ltd., 
Tokyo, Japan).
Biomarkers
Serum soluble HER3 and the HER3 ligand, heregulin 
(HRG) levels were also evaluated in all patients. Blood 
for serum biomarkers was collected on Day 1 (before 
administration), 8, 15, and 21 of Cycle 1, and Day 21 
of Cycle 2 and changes in both soluble HER3 and HRG 
serum levels were evaluated. Soluble HER3 levels were 
measured by enzyme-linked immunosorbent assay 
(ELISA). In addition, soluble HRG was also evaluated 
immunologically according to the previous report [24, 
25].
Statistical method
All patients who received study medication were included 
in the analysis of safety and efficacy. Safety and efficacy 
statistical analyses were performed by SAS System Release 
9.2 (SAS Institute Inc., Cary, NC, USA).
Results
Patient characteristics
Six Japanese patients with advanced NSCLC were enrolled 
and were evaluated in this study. The baseline character-
istics of the patients are summarized in Table  1. The age 
range was 54.0–78.0 years (median: 72.5 years), and all six 
patients harbored EGFR mutation (exon 19 deletion, n = 2; 
L858R,  n = 4; T790M,  n = 1). Five patients received prior 
EGFR-TKI therapies treated by at least any one of gefitinib, 
erlotinib, and afatinib, and one patient was an EGFR-TKI 
therapy naïve patient. The median number of prior chemo-
therapy regimens was 2 (range, 1 − 5). At the time of data 
cutoff, all patients had discontinued treatment: one because 
of an adverse event (grade 3 ILD), one because of patient 
withdrawal and four because of disease progression.
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Safety and tolerability
The DLTs occurring during cycle 1 were evaluated. No 
DLTs were observed in all patients. The AEs reported for 
all treatment cycles are summarized in Table 2.
The most common overall AEs (≥ 50 %) were diarrhea, 
stomatitis, dermatitis acneiform, dry skin, and paronychia 
which were generally mild and manageable. Most of the 
AEs were related to both patritumab and erlotinib and were 
generally mild and manageable. No grade 4 or grade 5 AEs 
occurred in this study. One patient discontinued both patri-
tumab and erlotinib treatment because of a drug-related 
AE. An elderly female patient with gefitinib-pretreated 
advanced NSCLC developed grade 3 ILD (onset, day 86); 
after the discontinuation of both patritumab and erlotinib 
treatment, steroid administration was conducted and ILD 
was resolving. No patients developed anti-patritumab anti-
bodies after the administration of patritumab Process 2 for-
mulation in this study.
Pharmacokinetics
Mean +/− sd serum concentration for patritumab Process 
2 formulation versus time is shown in Fig. 1, and descrip-
tive statistics for the PK parameters are summarized in 
Table 3. The mean area under the curve (AUC) value was 
2640 µg day/mL; the  Cmax value was 434 µg/mL; and the 
terminal half-live was 9.18 days, respectively.
Efficacy
One partial response (PR) and five cases with stable disease 
(SD) were observed. The PR was observed in an EGFR-
TKI naïve patient who had a tumor with an EGFR-acti-
vating mutation (L858R). Among the five SD patients, all 
patients received prior EGFR-TKIs (treated by at least any 
one of gefitinib, afatinib, and erlotinib) treatment (exon 19 
deletion, n = 2; L858R, n  = 3, T790M, n = 1). The median 
progression-free survival (PFS) (95 % confidence interval) 
was 222.0 (100.0–363.0) days.
Biomarker analysis (serum HER3 and heregulin)
Soluble serum HRG level was detectable in only a patient, 
subject No. 2, prior the administration (5,190.1  pg/ml), 
although was not detectable in other samples from five 
patients (Table  4). In addition, this patient maintained 
a most durable stable disease for 363 days among six 
patients, although tumor already acquired a resistance to 
gefitinib. The soluble HRG level was maintained on dur-
ing Cycles 1 and 2 in a patient subject No. 2 (7411.2 pg/
ml at Day 8 of Cycle 1; 6870.5 pg/ml at Day 15 of Cycle 
1; 5399.1  pg/ml at Day 21 of Cycle 1; and 5329.5  pg/ml 
at Day 21 of Cycle 2). Soluble HER3 level was various in 
serum obtained from six patients prior the administration 
(mean 7,475.8  pg/ml; 3,164.0–25,005.5  pg/ml, Table  4). 
Soluble HER3 level increased post the administration 
(mean 15,585.8 pg/ml at Day 8 of Cycle 1; 18,016.7 pg/ml 
at Day 15 of Cycle 1; 18,100.1 pg/ml at Day 21 of Cycle 1, 
Supple. Table 2).
Discussion
This phase 1 study was conducted primarily to evaluate the 
safety and tolerability of patritumab Process 2 formulation 
combined with EGFR-TKI, erlotinib in Japanese patients 
with advanced NSCLC. The safety and tolerability, PK, 
Table 1  Baseline patient characteristics
ECOG Eastern Cooperative Oncology Group, EGFR Epidermal 
Growth Factor Receptor
Characteristic Value




















 Exon 19 deletion 2
 L858R 4
 T790M 1
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anti-patritumab antibody, tumor response, and biomarkers, 
including sHER3 and sHRG, were explored in this study. 
Patritumab Process 2 formulation was developed to manu-
facture the drug substance with the aim of increasing the 
yield of the target protein and improving properties of the 
drug substance and/or product.
Regarding safety and tolerability, no DLTs were reported 
at all patients (patritumab Process 2 formulation at 9 mg/
kg every 3 weeks after initiation of 18 mg/kg loading dose 
with oral daily dose of erlotinib 150 mg). The most com-
mon AEs in this study were gastrointestinal and skin tox-
icities, which were generally mild and manageable and 
most AEs in this study were similar to the well-known side 
effects of EGFR-TKIs. No treatment-related deaths due 
to AEs were reported. Some SAEs were reported, includ-
ing grade 3 ILD, which was related to either patritumab or 
erlotinib treatment. An elder female patient with gefitinib-
pretreated advanced NSCLC developed grade 3 ILD (onset, 
day 86); after the discontinuation of both patritumab and 
erlotinib treatment, steroid administration was conducted 
and ILD was resolving.
PK parameters were calculated by non-compartmen-
tal model-based analysis, and  AUC0−21day and  Cmax were 
compared with existing data of former Process 1 formu-
lation combined with erlotinib in Japanese patients with 
non-small cell lung cancer. The  AUC0−21day and Cmax 
(Mean ± SD) of the Process 2 formulation were 2640 ± 544 
µg day/mL and 434 ± 121 µg/mL, respectively, suggesting 
almost comparable exposure obtained with Process1 for-
mulation  (AUC0−21day and  Cmax: 2480 ± 420 µg day/mL and 
400 ± 46.7 µg/mL, respectively) [22]. Furthermore, no neu-
tralizing antibodies were detected in patients in this study 
Table 2  Adverse events in more than 20 % of patients
Preferred Terms are coded using MedDRA version 19.0




Dermatitis acneiform 6 (100.0)
Dry skin 5 (83.3)
Paronychia 4 (66.7)
Nail infection 2 (33.3)
Tumour pain 2 (33.3)
Decreased appetite 2 (33.3)
Insomnia 2 (33.3)
Malaise 2 (33.3)
























0 1 3 7 14 21 42 63
Fig. 1  The mean ± sd serum concentration for patritumab Process 2 formulation versus time
Table 3  Summary of pharmacokinetic parameters of patritumab (U3-1287) Process 2 formulation in Japanese patients with advanced NSCLC
Cmax maximum observed serum concentration, Tmax time of maximum observed serum concentration, AUC0 − 21day area under the concentra-
tion–time curve from day 0 to day 21, AUC0−∞ area under the concentration–time curve from day 0 to infinity, t1/2 elimination half-life, Vss the 
terminal phase volume, CL clearance, CV coefficient of variation
Cmax, µg/mL, 
mean (CV%)
Tmax, days, mean 
(range)











(n = 6) 434 (27.9) 0.09 (0.05–0.18) 2640 (20.6) 3310 (24.8) 9.18 (23.2) 69.5 (18.1) 5.70 (22.4)
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after patritumab Process 2 formulation administration, as 
assessed by an anti-patritumab antibody and cell-based bio-
assay, similar to findings in the previous studies.
In regard to the clinical efficacy of the combined treat-
ment, 1 PR and 5 cases with SD were observed among 
six patients. The PR patient had a tumor with an EGFR-
activating mutation (L858R) and EGFR-TKI naïve set-
ting. Among six patients, five patients had available infor-
mation about T790M status of their tumor by conducting 
pre- or post-biopsy of tumor tissue when patients devel-
oped disease progression against preceding EGFR-TKIs 
therapy. Although this was limited patients’ number, one 
key remarkable point about potential clinical efficacy in 
this study is that durable progression-free survival was 
observed (363, 100, and 297 days) in three T790M wild-
type EGFR-TKI refractory patients. These results were 
encouraging, because they were similar or superior to those 
obtained with use of the third generation EGFR-TKI, osi-
mertinib (AZD9291) in recent clinical study in patients 
with previously treated NSCLC and sub-population analy-
sis of patients with no detectable EGFR T790M (69 % of 
the patients had an estimated response duration of 6 months 
or longer, with a median progression-free survival of 2.8 
months (95 % CI, 2.1 to 4.3; 71 % maturity) in 62 patients 
with no detectable EGFR T790M [26].
The current study observed that a patient had a high 
level of soluble HRG in serum and maintained most 
durable stable disease, although tumor already acquired 
a resistance to gefitinib. Previous studies proved that 
HRG expression level correlated with the efficacy of sev-
eral kinds of anti-HER3 antibody preclinically as well 
as clinically [25, 27–30]. U3-1287 also inhibited cell-
proliferation in aberrantly heregulin-expressing NSCLC 
cells [28]. Furthermore, Patritumab combination with 
erlotinib demonstrated a significantly improved progres-
sion-free survival in patients with advanced NSCLC and 
high level of soluble HRG in serum compared to placebo 
combination [25]. Although the current study analyzed 
limited samples, patritumab plus erlotinib might be opti-
mal in patients with EGFR-mutant NSCLC and high 
level of HRG expression.
In conclusion, patritumab Process 2 formulation at a 
dose of 18 mg/kg for the initial dose and at 9 mg/kg for 
the second and subsequent doses every 3 weeks in com-
bination with an oral daily dose of erlotinib 150 mg was 
determined to be feasible in regard to the tolerability in 
Japanese patients with advanced NSCLC. Although some 
limitations including small patients number exist in this 
study, preliminary demonstration of both favorable PK 
profiles and the efficacy of the combined treatment was 
encouraging, potentially in NSCLC patients with EGFR-
activating mutations, where prior EGFR-TKI treatment 
failed regardless of EGFR T790M status.
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Table 4  Patient characteristics and soluble HER3 expression in serum
PR partial response, SD stable disease










HER3 concentration in serum, pg/ml
Day 1 of 
Cycle 1
Day 8 of 
Cycle 1
Day 15 of 
Cycle 1




1 L858R Naïve PR 187 4493 13,476 15,741 17,527 19,060
2 Exon 19 dele-
tion
Treated SD 363 3862 12,058 16,284 16,366 18,687
3 L858R Treated SD 100 4023 11,439 14,411 14,464 15,580
4 L858R Treated SD 297 3164 9002 11,587 12,914 13,399
5 L858R/
T790M
Treated SD 257 25,006 35,006 37,062 33,052 35,890
6 Exon 19 dele-
tion
Treated SD 101 4308 12,534 13,016 14,280 18,544
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